English
Home > Products > CAS NO 2380-63-4

China CAS NO 2380-63-4 Factory

We insist over the principle of enhancement of 'High high quality, Efficiency, Sincerity and Down-to-earth working approach' to offer you with superb assistance of processing for CAS NO 2380-63-4,2380-63-4,Ibrutinib intermediate,Ibrutinib advance intermediate,4-Aminopyrazolo[3,4-d]pyrimidine, Top quality, timely company and Aggressive cost, all win us a superior fame in xxx field despite the international intense competition.
CAS NO 2380-63-4, We also provide OEM service that caters to your specific needs and requirements. With a strong team of experienced engineers in hose design and development, we value every opportunity to provide best products for our customers.

Related Products

Hot Products

  • 7-Hydroxyquinolinone

    7-Hydroxyquinolinone

    Product Name:7-Hydroxyquinolinone
    Molecular Formula:C9H7NO2
    Molecular Weight:161.16
    CAS Registry Number:70500-72-0
  • DICALCIUM PHOSPHATE DIHYDRATE

    DICALCIUM PHOSPHATE DIHYDRATE

    Product Name:DICALCIUM PHOSPHATE DIHYDRATE
    Molecular Formula:CaH7O5P
    Molecular Weight:158.1
    CAS Registry Number:7789-77-7
  • (R)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine

    (R)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine

    Product Name:(R)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine
    Molecular Formula:C12H19NO4S
    Molecular Weight:273.35
    CAS Registry Number:608142-27-4
  • Cinacalcet hydrochloride

    Cinacalcet hydrochloride

    Product Name:Cinacalcet hydrochloride
    Molecular Formula:C22H23ClF3N
    Molecular Weight:393.88
    CAS Registry Number:364782-34-3
  • 4-Nitrobenzyl chloroformate

    4-Nitrobenzyl chloroformate

    Product Name:4-Nitrobenzyl chloroformate
    Molecular Formula:C8H6ClNO4
    Molecular Weight:215.59
    CAS Registry Number:4457-32-3
  • Methyl trifluoroacetate

    Methyl trifluoroacetate

    Product Name:Methyl trifluoroacetate
    Molecular Formula:C3H3F3O2
    Molecular Weight:128.05
    CAS Registry Number:431-47-0
  • Related Blog
  • Reviews

  • What Is Misoprostol Used For?

    Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer, the prevention of anti-inflammatory induced peptic ulcer and the prevention of early pregnancy.It has the function of inhibiting the secretion of gastric acid and preventing the formation of ulcer, thus protecting the gastric mucosa...

  • CAS 148553-50-8 What is Pregabalin?

    Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses within the brain that cause seizures. Pregabalin also affects chemicals within the brain that send pain signals across the systema nervosum.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept